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As compared to patients of Group 1, those of Group 2 were younger (47±14 vs 41±15 
years, p<0.001), and showed less advanced LV dysfunction (EF 28±9 vs 35±9%, 
p<0.001) and remodelling (end-diastolic diameter index 38±7 vs 35±7 minim2, p<0.001) 
at the time of diagnosis. Most patients of Group 1 and 2 were treated with ACE-I (93% 
and 88%, p=NS) and BB (83% and 74%, p<0.05). 
Five and 10-year transplant-free survival was respectively 73 and 57% in Group1 vs 93 
and 86% in Group 2, while hospitatisation-free survival was 47 and 32% in Group1 vs 70 
and 57% in Group 2 (both p<0.001). No outcome difference was observed between 
Group 2a and 2b, whereas 5 and 10-year transplant-free survival was significantly better 
in patients of Group 2 who were treated with BB than in those not receiving BB (p=0.007 
after stratification for the severity of the disease). 
At 6 to 8 years of follow-up, 38% of patients of Group 2 developed HF symptoms, and/or 
a decrease of LVEF>10%, and/or the need of hospitalisation for cardiovascular reasons. 
The long-term progression of HF symptoms and LV dysfunction was similar in asymp- 
tomatic patients of Group 2a and 2b and not significantly different to that of patients of 
Group 1. 
Even though asymptomatic DC patients receiving an optimal medical treatment are char- 
acterized by low rates of death or heart transplant, nevertheless during a long-term fol- 
low-up they frequently exhibit a worsening of clinical status and LV function. Our data 
suggest that in these patients an early and aggressive BB strategy should be carefully 
considered in order to counteract as much as possible the Ioeg-term progression of the 
disease. 
1158-150 Functional Significance of Myocyte Endothelin-1 in 
Experimental Chronic Chagasic Cardiomyopathy 
Madhuiika Chandra. Herbert B, Tanowitz, Yaz Y. Kisanuki, Masashi Yanagisawa, 
Jamshid Shirani, Albert Einstein College of Medicine, Bronx, New York. 
Background. Trypanosorna cruzi, the etiologic agent of Chagas' disease, is an important 
cause of chronic cardiomyopathy. Endothelin-1 (ET-1) has been implicated in the patho- 
genesis of chronic chagasic heart disease, possibly due to its effect on the coronary 
microvasculature. Aim and Methods, In order to assess the role of ET-1 in the patho- 
genesis of chronic chagasic cardiomyopathy, we infected ET-1 (flox/flox); (x-MHC-Cre (+) 
(ETKO) mice, in which the ET-1 gene has been deleted from cardiac myocytes, with 104 
trypomastigotes of T. cruzi (Brazil strain). We also infected ET-1 (flox/flox); Cre (-) (FLOX) 
mice. Uninfected littermates of both groups served as controls. All mice (n=28) survived 
and were evaluated at 160-170 days post infection by transthoracic echcoardiography. 
Left ventricular (LV) end diastolic diameter (EDD), relative wall thickness (RWT), and 
fractional shortening (FS) were measured. Right ventricular (RV) size was assessed 
semi-quantitatively on a scale of 0-3. Results. Compared with their respective, unin- 
fected controls, both infected ETKO and FLOX mice had increased LV EDD[(3.8±0.3 v 
2.7±0.1mm, FLOX), and (3.0±0.1 v 2.6±0.1mm, ETKO), both p<0.05], along with 
reduced LV FS[(40±3 v 53±1%, FLOX) and (47±2 v 56±2%, ETKO), both p<0.05] and 
RWT[(0.4±0.0 v 0.5±0.0, FLOX) and (0.5±0.0 v 0.6±0.0 ETKO), both p<0.05]. However 
the magnitude of these changes was attenuated in the infected ETKO group as com- 
pared with the infected FLOX group (p<0.05 for LV EDD, RWT, and FS). Similarly, RV 
was larger in infected FLOX compared with ETKO (2.5±0.3 v 0.6±0.3, respectively, 
p<0.01). Conclusions. These data provide support for the role of ET-1 in pathogenesis 
and progression of chronic chagasic heart disease and indicate that the cardiac myocyte 
is an important source of ET-1 in this disease. 
1158-151 Mitochondrial Respiratory Abnormalities in Ventricular 
Myocardium of Patients With End-stage Congenital 
Heart Disease 
Seema Mital, Alessandro Barbone, Ralph J. Mosca, Jan M. Quaegebeur, Linda J. 
Addonizio, Thomas H. Hintze, Columbia University, New York, New York. 
Background: Nitric oxide (NO) binds to mitochondrial cytochrome oxidase to decrease 
myocardial oxygen consumption (MVO2). This regulation is disrupted in end-stage heart 
failure in part due to reduced'NO availability. We compared NO mediated regulation of 
MVO2 in patients with end-stage congenital heart disease (CHD) vs cardiomyopathy 
(CMP) undergoing cardiac transplantation. 
Methods: MVO2 was measured in vitro using a Clark type oxygen electrode in LV muscle 
segments obtained from explanted failing human hearts at heart transplantation. This 
included 7 Lots with complex CHD (mean age 11±10 years) and 14 pts with dilated CMP 
(mean age 25±26 years). We measured the effect of increasing doses (10-7-10-4M) of 
the following NO agonists on MVO2 - amlodipine, ramiprilat, bradykinin - all of which 
cause kinin-dependent NO production, and exogenous NO donors, S-nitroso N-acetyl 
penicillamine (SNAP) and nitroglycerin (NTG). MVO2 was measured with and without 
addition of nitro-L-arginine methyl ester (L-NAME, 10-4 M), NO synthass inhibitor. 
Results: All drugs caused a significant dose-dependent decrease in MVO2 in both 
groups. However, myocardium from CHD pts showed a smaller decrease in MVO2 in 
response to NO agonists compared to CMP pts. Changes in MVO2 at highest dose in 
C;HD vs CMP respectively are shown - amlodipine, -5±7% vs -29±6%, p<O.O01; ramipri- 
lat, -17±8% vs -26±2%, p=O.05; and bradykinin, -22±7% vs -30±5%. NO donors, SNAP 
and NTG also caused smaller decreases in MVO2 in CHD vs CMP (SNAP, -37±4% vs - 
49±3% and NTG, -16±6% vs -37±4% raspectively)(p<0.01). Therefore, NO donors were 
unable to completely reverse altered regulation of MVO2 in CHD suggesting abnormal 
mitochondrial function. L-NAME, NO inhibitor, attenuated the effect of amlodipine, ramip- 
rilat and bradykinin but not of SNAP and NTG. 
Conclusion: Abnormal regulation of MVO2 in end-stage heart failure may be secondary 
to reduced NO availability and can be reversed by use of NO agonists. In end-stage 
CHD, however, this abnormality may be related at least in part to abnormal mitochonddal 
function. 
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1158-152 Improved Glycemic Control Induces Regression of Left 
Ventricular Mass in Patients With Type 1 Diabetes 
Mellitus 
Fr~,nz C. Aeofelbacher. Susan B. Yeon, Larry A. Weinrauch, John D'Elia, Andrew J. 
Burger, Beth Israel Deaconess Medical Center, Boston, Massachusetts, Joslin Diabetes 
Center, Boston, Massachusetts. 
Background: Diabetes mellitus has been associated with abnormalities of cardiac func- 
tion and left ventrioular hypertrophy. However, the effect of improved glycomic control on 
these parameters is controversial and may be confounded by the type of glycemic ther- 
apy or alterations in blood pressure levels. 
Methods: We studied 19 patients (mean age 40 ± 9 years) with longstanding type I dia- 
betes mellitus (28 ± 4 years), who participated in a program of stringent glycomic control 
using insulin injections. Glycemic control was monitored with hemoglobin Alc (Hb Alc) 
levels; improvement was defined as > 1% (absolute) decrease of Hb Alc. Two-dimen- 
sional and Doppler echocardiegrams and 24-hour ambulatory blood pressures (24h 
ABP) were obtained at baseline and after 1 year. Left ventricular (LV) mass was deter- 
mined using the area-length method. 
Results: Hb Alc and echocardiographic data (mean + SD) are shown below. Septal 
thickness decreased for all patients; septal thickness and LV mass regressed for the sub- 
group with improved glycemic control. Left ventricular function and 24h ABP parameters 
remained unchanged after 1 year in both groups. 
Conclusions: Improved glycemic control induces regression of septal thickness and LV 
mass without significant effect on systolic or diastolic function, importantly, these 
changes occurred in the absence of significant alterations in 24h ABP levels. 
All Patients (n=19) Patients with improved 
glycemic control (n=12) 
Baseline 1 Year Baseline 1 Year 
Hemoglobin Alc (%) 9.5 ± 1.6 8.2 ± 1.5" 9.8 ± 1.5 7.8 ± 1.2" 
LV mass (gm) 203 ± 53 185 ± 59 205 ± 35 182 ± 46"i" 
LV septum (mm) 10.3 ± 1.3 9.7 ± 1.6t 10.3 ± 1.4 9.4 ± 1.7"i" 
LV posterior wall (mm) 9.9 ± 1.4 9.6 ± t .1 9.9 ± 1.3 9.6 ± 0.9 
LV diastolic diameter (ram) 46 ± 5.8 46.9 ± 5.7 45.3 ± 4.1 46.3 ± 4.1 
LV systolic diameter (mm) 28.2 ± 4.2 28.3 ± 5.8 27.4 ± 3.6 27.7 ± 4.9 
Fractional shortening (%) 38.7 ± 5.3 40.2 ± 6.9 39.5 ± 5.7 40.5 ± 6.9 
E/A ratio of mitral inflow 1.23 ± 0.4 1.29 ± 0.5 1.25 ± 0.4 1.33 ± 0.5 
E-wave deceleration time (ms) 191 ± 40 188 ± 37 176 ± 33 190 ± 40 
*p<O.O01 vs baseline, tp<0.05 vs baseline 
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1159-137 Impact  of  Percutaneous Coronary Intervention on 
Functional Status: Results from the ADORE Trial 
Sabdna Cuono. Mark J. Eisenberg, James Blankenship, Thao Huynh, Michael Azrin, 
Steven Sedlis, Louise Pilote, Jewish Genera/Hospital Montreal Quebec, Canada. 
Background: 
While it is well known that percutaneous coronary intervention (PCI) is effective at reduc- 
ing angina and other markers of coronary artery disease (CAD), little is known about the 
magnitude of functional status and angina class improvement as well as the magnitude 
of anti-anginal drug use after PCI in the general post-PCI patient population. 
Method: 
To determine the magnitude to which PCI effects functional status, angina ctass and anti- 
anginal drug use, 9-month post-PCI results were compared with results obtained 3- 
months prior to PCI in 109 patients. Patients were enrolled in the Aggressive Diagnosis 
Of Restenosis (ADORE) Trial, a randomized clinical trial which examined functional test- 
ing in patients who underwent complete coronary revasculadzation by a percutaneous 
technique, 
Results: 
A significant improvement in functional status, measured by an increase in METS, was 
observed 9-months after PCI when compared to 3-months prior (9.7 vs 7.4, p<0.0001). In 
addition, a significant difference was found between 9-month post-PCI functional test 
results and those obtained 3-months prior: reversible ischamia detected by ECG (19.4 vs 
63.0, p< 0.0001 ), clinically determined reversible ischemia (10.2 vs 58.6, p<0.0001 ), and 
electrically or clinically positive functional test result (23.4 vs 83.7, p<0.0001). A signifi- 
cant improvement in CCS angina class was also found post-PCI (CCS class 1 or 2:24.5 
vs 43.5, p=0.001, and CCS class 3 or 4:1.0 vs 46.3, p<0.0001). A marked decrease in 
anti-anginal drug use was further noted after PCI (16.0 vs 30.6, p=0.0001). 
Conclusions: 
Complete revasculanzation with PCI leads to substantiat improvements in functional sta- 
tus and CCS angina class, and is associated with decreased use of anti-anginal 
drugs.Thus, this procedure is beneficial in patients with CAD. 
